SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Österlund J.) "

Sökning: WFRF:(Österlund J.)

  • Resultat 1-10 av 107
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Michelsen, B., et al. (författare)
  • Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
  • 2020
  • Ingår i: RMD open. - : BMJ. - 2056-5933. ; 6:3
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
  •  
2.
  •  
3.
  •  
4.
  • Sagrado Garcia, I. C., et al. (författare)
  • Neutron production in neutron-induced reactions at 96 MeV on (56)Fe and (208)Pb
  • 2011
  • Ingår i: Physical Review C. Nuclear Physics. - 0556-2813 .- 1089-490X. ; 84:4, s. 044619-
  • Tidskriftsartikel (refereegranskat)abstract
    • Double-differential cross sections for neutron production were measured in 96-MeV neutron-induced reactions at The Svedberg Laboratory in Uppsala, Sweden. Measurements for Fe and Pb targets were performed using two independent setups: DECOI-DEMON, time-of-flight telescope dedicated to the detection of emitted neutrons with energies between a few and 50 MeV and CLODIA-SCANDAL device devoted to measuring emitted neutrons with energies above 40 MeV. Double-differential cross sections were measured for an angular range between 15 and 98 deg and with low-energy thresholds (approximate to 2 MeV). Angular and energy distributions and total neutron emission cross sections have been obtained from those measurements. Results have been compared with predictions given by different models included in several transport codes (MCNPX, GEANT, TALYS, PHITS, and DYWAN) and with other experimental data (the EXFOR database).
  •  
5.
  • Sahin, Cagla, et al. (författare)
  • Structural basis for dityrosine-mediated inhibition of alpha-synuclein fibrillation
  • Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
    • α-synuclein (aSyn) is a small intrinsically disordered protein which can self-assemble into highly organized β-sheet structures that are found to accumulate in plaques in the brain of Parkinson’s Disease patients. Oxidative stress has been shown to be important for aSyn and its self-assembly. Here we characterize the molecular and structural effects that mild oxidation has on aSyn monomer and its aggregation. Using a combination of biophysical methods, SAXS and native ion mobility mass spectrometry, we find that oxidation leads to formation of intramolecular dityrosine cross-linkages that reduce aSyn’s size by a factor of √2. MD simulations support our experimental results showing a stable and compact aSyn conformation that prevents self-assembly and amyloid formation by steric hindrance, suggesting an important role of mild oxidation in preventing amyloid formation. 
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Hildebrand, Angelica, et al. (författare)
  • Elastic Neutron Scattering at 96 MeV
  • 2004
  • Ingår i: Proc. Int. Conf. on Nuclear Data for Science and Technology.
  • Konferensbidrag (övrigt vetenskapligt/konstnärligt)
  •  
10.
  • Hildebrand, A, et al. (författare)
  • Elastic neutron scattering at 96 MeV
  • 2005
  • Ingår i: Proc. of the Int. Conf. on Nuclear Data for Science and Technology: Santa Fé, New Mexico, USA, September 26-October 1, 2004. ; , s. 853-
  • Konferensbidrag (refereegranskat)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 107
Typ av publikation
tidskriftsartikel (54)
konferensbidrag (47)
annan publikation (5)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (92)
övrigt vetenskapligt/konstnärligt (11)
populärvet., debatt m.m. (4)
Författare/redaktör
Blomgren, J (49)
Österlund, M. (47)
Pomp, S (39)
Tippawan, U (38)
Nilsson, L. (32)
Pomp, Stephan (32)
visa fler...
Österlund, Michael (32)
Jonsson, O. (28)
Prokofiev, A.V. (28)
Mermod, P. (27)
Olsson, N (27)
Klug, J (24)
Renberg, P-U (22)
Nadel-Turonski, P. (21)
Johansson, Cecilia (19)
Bergenwall, B (18)
Dangtip, S (18)
Blomgren, Jan (17)
Lecolley, F.-R (17)
Öhrn, A (16)
Hildebrand, A (15)
Haddad, F. (14)
Prokofiev, A (13)
Tippawan, Udomrat (13)
Lecolley, J.-F (13)
Blideanu, V. (13)
Watanabe, Y. (12)
Marie, N (11)
Elmgren, K (11)
Ekström, C (10)
Alhassan, Erwin (10)
Prokofiev, Alexander ... (10)
Ziemann, V (10)
Eudes, Ph. (10)
Nilsson, Leif (9)
Gustavsson, Cecilia (9)
Sjöstrand, Henrik (9)
Le Brun, C (9)
Olsson, Nils (8)
Reistad, D. (8)
Byström, O (8)
Wessman, D (8)
Atac, A (8)
Koning, A. J. (8)
Guertin, A. (8)
Lefort, T. (8)
Louvel, M. (8)
Mermod, Philippe (8)
Hayashi, M. (7)
Marie-Noury, N (7)
visa färre...
Lärosäte
Uppsala universitet (92)
Karolinska Institutet (8)
Kungliga Tekniska Högskolan (7)
Göteborgs universitet (3)
Umeå universitet (3)
Stockholms universitet (3)
visa fler...
Lunds universitet (2)
Chalmers tekniska högskola (2)
Luleå tekniska universitet (1)
Linköpings universitet (1)
visa färre...
Språk
Engelska (106)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (41)
Medicin och hälsovetenskap (11)
Teknik (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy